We were concerned, as such tumor growth could be a possible adverse effect of bevacizumab. in two eyes (2/9; 22%) after IVB, and in three eyes (3/4; 75%) after TTT. Among five patients who underwent TTT after IVB, four patients (4/5; 80%) demonstrated additional advantage. All IVBs could not reduce tumor sizes. Rather, tumor growth was detected in seven out of 14 eyes (7/14; 50%) that underwent IVB. None of the patients who underwent TTT showed tumor growth. The lack of treatment response to IVB was suggestive of malignancy, as most small pigmented lesions that had no response to IVB showed tumor growth (86%, intravitreal bevacizumab injection, transpupillary thermotherapy, number, subfoveal fluid, best corrected visual acuity, Follow-up duration, months, largest base diameter, male, female, Observation, Therapy, hand motion, subfoveal fluid, best corrected visual acuity, intravitreal bevacizumab injection, transpupillary thermotherapy, number Among 14 patients who received IVB as the primary therapy, five underwent Dantrolene TTT as an additional treatment. Following TTT, four out of these five patients (4/5; 80%) demonstrated an additional advantage. Complete resolution of SFF occurred in two eyes (2/5; 40%), and partial resolution occurred in two eyes (2/5; 40%; Table?3). Table 3 Assessment of Treatment Response in the Patients Receiving Additional TTT after IVB as Primary Treatment for Subfoveal Fluid intravitreal bevacizumab injection, transpupillary thermotherapy, number, Therapy, primary, secondary, Dantrolene subfoveal fluid, male, female Of the nine eyes that received IVB alone, visual acuity improved in two eyes (2/9; 22%), remained stable in two eyes (2/9; 22%), and Dantrolene worsened in five eyes (5/9; 56%). Of the eyes that underwent TTT alone, visual acuity improved in three eyes (3/4; 75%), and remained stable in one eye (1/4; 25%)(Table?2). Despite the small number of enrolled patients, TTT showed better effects than IVB, in terms of fluid reduction and visual improvement. Figure?1 depicts the findings of a patient who showed complete resolution of SFF, improved visual acuity, and reduced tumor size after TTT. Open in a separate window Fig. 1 Treatment results of transpupillary thermotherapy for subfoveal fluid associated with choroidal melanocytic lesions. A 23-year-old man (Case 15) presented with 2-year history of decreased visual acuity of the left eye. His initial best corrected visual acuity (BCVA) was 20/63. a There was a pigmented subretinal mass supero-temporal to the fovea, b with a height of 2.24?mm and base diameter of 7.17?mm, as measured by B-scan ultrasonography. c Initial optical coherence tomography showed subretinal fluid at the macula. f After four sessions of transpupillary thermotherapy, subretinal fluid completely resolved and BCVA improved to 20/25. d The tumor showed scarring changes, and (e) tumor size decreased to 1 1.32?mm (height) by 4.13?mm (base diameter), as measured by B-scan ultrasonography. Improved vision and attached retinal status were maintained for 46?months after the last treatment. Tumor size further decreased to 0.50?mm (height) by 4.18?mm (base diameter) Among 15 eyes that received IVB or observation as the primary therapy, tumor growth was detected in seven eyes (7/15; 46.7%) (patients 1, 2, 3, 10, 11, 12, and 13). Of the patients who underwent TTT alone, none of them demonstrated tumor growth (0/4, 0%). IVB was not effective in inhibiting tumor growth. Of the patients who were followed up for at least 11?months, seven patients (7/18, 38.9%) showed tumor growth during follow-up (mean, 46.9?months; range, 11C86?months). With the assumption of choroidal melanoma, we Dantrolene advised these seven patients with enlarged tumors to undergo further treatment. Four patients received ruthenium-106 brachytherapy (patients 2, 11, 12, and 13), one patient underwent TTT (patient 10), and one patient underwent enucleation (patient 3). Mouse monoclonal to HDAC3 One patient was advised to undergo brachytherapy, but he refused and was lost to follow-up (patient 1). In fact, one patient showed accelerated tumor growth after IVBs (Fig.?2). This 58-year-old man had presented with a 1-month history of decreased visual acuity. A pigmented choroidal mass was noted at the fovea with a height of 2.06?mm and base diameter of 5.29?mm, as measured by B-scan ultrasonography and fundus photography. Calculated tumor volume was 30.18?mm3. Shallow SFF was observed on OCT. There was no Dantrolene change in tumor size over the 4.5-month follow-up period without any.